Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

CEOs and Contract Manufacturers
Targeted in Latest Warning Letters

This article was originally published in The Gold Sheet

Executive Summary

FDA sent six of its last nine drug GMP warning letters to contract manufacturing facilities. Most of the letters emphasized corporate accountability, and many went directly to CEOs.

You may also be interested in...



FDA Drug GMP Warning Letters Increase 6%, Focus on Supply Chain and Sterility Assurance in FY 2011

The number of drug GMP warning letters issued by FDA continued to climb in fiscal year 2011, with supply chain and sterility assurance issues dominating the agency’s attention. FDA is requesting a budget increase in FY 2013 to expand its inspectional presence abroad to better meet global supply chain threats, and agency officials are saying that failure to monitor contract manufacturers is a major problem shown in recent warning letters, but that failure to investigate out-of-specification results is still the No. 1 finding.

Another Busy Year of Drug Recalls Led to Shortages of Injectables

Manufacturers recalled more drug products from the U.S. market in 2010 than they had in any year but 2009.

Another Busy Year of Drug Recalls Led to Shortages of Injectables

Manufacturers recalled more drug products from the U.S. market in 2010 than they had in any year but 2009.

Latest News
See All
UsernamePublicRestriction

Register

PS000566

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel